Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer

[News]

While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the...

More... (http://www.medicalnewstoday.com/releases/309113.php)